182 results about "Carcinoma prostate" patented technology

The present invention provides treatment regimens for treating diseased prostate tissue, including the steps of chemically ablating prostate tissue and coadministering an antiandrogen. In some embodiments, prostate tissue is chemically ablated by injection of ethanol, or an injectable gel comprising ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal antiandrogen is bicalutamide. The treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic hyperplasia and prostatic carcinoma. The invention further provides a treatment regimen for treating benign prostatic hyperplasia, including the steps of damaging prostate tissue and coadministering an antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen drug, and a means for administering the antiandrogen drug. A kit including a first surgical device for delivering a chemoablation fluid to prostate tissue transurethrally, an antiandrogen drug such as bicalutamide, and a second surgical device for administering the antiandrogen drug, is further provided.

The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

The present invention relates to a method capable of using natural and artificial synthetic isosulfocyanate compound or its derivative to prevent and cure prostatic diseases and skin carcinoma. The internal tests show that various isosulfocyanate compounds or their derivatives can induce prostatic cell II phase drug metabolic detoxication enzyme-glutathione transferase so as to can inhibit the hyperplasia of prostate and inflammation, and can prevent and cure prostatic carcinoma and skin carcinoma.

The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and / or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and / or prostate cancer.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

The present invention includes using optical spectroscopy as an innovative technique for ex-vivo demonstration of renal and prostate tumors. The apparatus and methods disclosed herein demonstrate the ability of optical spectroscopy to reliably differentiate tumor from normal tissue in renal specimens.

We have discovered a protein in humans, herein referred to as thymosin R16 (SEQ ID NO: 1), that is expressed in human prostate cancer tumors but not in specimens of benign prostate hyperplasma (BPH) tissues. In contrast, prostate specific antigen (PSA), the gold standard of prostate cancer diagnosis, is highly expressed in BPH tissues. Increased expression of thymosin (316 has a high correlation to disease state in a number of cancers including prostate cancer and cancers of epithelial origin. Accordingly, method of diagnosing and prognosing cancer in a patient by measuring the level of thymosin (316 in a biological test sample obtained from the patient are provided.

The present invention relates to a pentacyclic triterpanoid derivative of multiple-oxide substitution of the A ring and the medicine salt or solvate of the derivative, and the present invention also relates to the preparation method, the drug combination, and medical use of the derivative. The compound of the present invention has the functions of inhibiting the activity of six human tumor cell strains in vitro, such as human prostate cancer cell (PC-3), nasopharyngeal carcinoma cells (CNE), oral squamous carcinoma cell(KB), human lung cancer cell (A549), human hepatoma cell (BEL-7404), and human cervix cancer cell (Hela), and the function of the invention is at the same magnitude of the positive control of cisplatin, thereby the compound can be used as expected antitumor drug. The compound of the present invention also inhibits the alpha glucosidase strongly, and the inhibiting effect is greater than the positive control of acarbose, thereby the compound can be used as expected medicine for preventing and treating diabetes and the treatment of the virus diseases.

Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.

The invention discloses a fly maggot extractive containing the principal components of water-soluble proteins, and the water-soluble proteins contained in the fly maggot extractive have the mass percentage of 50-70 percent and the molecular weight of 2-16 KDa. The fly maggot extractive not only has obvious inhibiting effect on human promyelocytic leukemia HL-60 cells, human erythroleukemia K562 cells, human liver cancers SMMC-7721, mouse leukemia P388 cells, human lung adenocarcinoma A549 cells, human nasopharyngeal darcinoma CNE cells, human prostatic carcinoma PC3 cells, human cervical carcinoma HeLa in vitro, but also has outstanding inhibiting effect on mouse S180 sarcomas and mouse Heps liver cancer solid tumors, and also has the effect on enhancing the humoral immunity of organisms. The invention also discloses a preparation method of the fly maggot extractive. The preparation method is easy and convenient for operation and control and low in cost and is suitable for industrialized production.

The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

The recombinant protein vaccine is a fusion protein formed from connection of BCG vaccine heat shock protein 65 with 1-5 copies of human prostatic specific antigen cytotoxin T lymphocyte polyepitope,in which the single-copy polypeptide of said human prostatic specific antigen cytotoxin T lymphocyte polyepitope possesses amino acid sequence showed by SEQ ID NO:2, and the double single-copy polypeptide of the human prostatic specific antigen dcytotoxin T lymphocyte polyeptope possesses amino acid sequence showed by SEQ ID NO:4. After it is applied in human body, it can effectively prevent and cure carcinoma of prostate. Said invention also provides the gene for coding said two kinds of recombinant protein vaccines.

Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues include Euonymus europaeus lectin (EEL); Psophocarpus Tetragonolobus Lectin-I (PTL-I); Griffonia Simplicifolia Lectin-I-A4 (GSL-I-A4); Griffonia Simplicifolia Lectin-I-B4 (GSL-I-B4); Sambucus nigra I agglutinin (SNA-I; Phaseolus vulgaris-L (PHA-L; Galanthus nivalis agglutinin (GNA); Narcissus pseudonarcissus agglutinin (NPA); Artocarpus integrifolia agglutinin (Jacalin); and mAb TM10 (IgM).

The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein.

The invention discloses a targeting multifunctional carbon nanotube / polyethylenimine drug delivery carrier for prostate cancer. A carbon nanotube with a diameter of 10-20nm and an average length of less than 300nm has carboxyl groups on surface thereof, and is modified by branched polyethylene imine; amino groups on polyethylene imine are utilized to further modify the carbon nanotube by connecting dansyl luminescent groups and human prostate stem cell antigen ( PSCA ) antibody. Method for preparing the material comprises steps of: refluxing the carbon nanotube in concentrated sulphuric acid and concentrated nitric acid to prepare the carbon nanotube with carboxyl groups on surface thereof; and then cladding branched polyethylene imine onto the surface of the carbon nanotube through amide bonds to enable the carbon nanotube with good water solubility and a large number of amino groups on surface thereof; and then attaching sulfonyl groups and PSCA antibody to the surface of the carbon nanotube through the amino groups. The drug delivery carrier prepared by the invention has good biocompatibility, little material toxicity, strong drug load capability, and good luminescent properties and targeting properties.

Methods for treating a patient suffering from a neoplastic disease are disclosed and described. A number of diseases can be treated under the present methods, including without limitation gall bladder cancer, hepato cellular cancer, ovarian cancer, small intestine cancer, lung cancer, mesothelioma, breast cancer, kidney cancer, pancreas cancer, prostate cancer, carcinoid cancer, leiomyosarcoma, or metastasis thereof. A general method for providing such treatment may include: 1) identifying in a patient one or more sentinel and / or metinel lymph nodes draining the neoplasm; 2) resecting the one or more nodes and, optionally all or part of the tumour or metastasis; 3) isolating tumour-reactive T-lymphocytes from said lymph nodes; 4) in vitro expanding said tumour-reactive T-lymphocytes; and 5) administering the thus obtained tumour-reactive T-lymphocytes to the patient.

The invention relates to a pharmaceutical composition containing an FGFR4 inhibitor, in particular to the pharmaceutical composition containing the FGFR4 inhibitor with a structure shown in a formula(I). The pharmaceutical composition developed by the invention has strong inhibition effect on FGFR4 kinase activity, and can be widely used for preparing medicaments for treating cancers, especiallyliver cancer, gastric cancer, prostate cancer, skin cancer, ovarian cancer, lung cancer, breast cancer, colon cancer, pancreatic cancer, esophageal cancer, glioma or rhabdomyosarcoma. (See the instruction for specific formula).

The invention discloses a composition with an effect of preventing and treating cancers. The composition is mainly prepared from the following Chinese herbal medicines in percentage by mass: 20 to 85 percent of airpotato yam rhizome and 15 to 80 percent of Chinese angelica. The Chinese medicinal composition has the effect of preventing and treating the cancers, can eliminate the limit that liver injury is easily induced by chemotherapeutic medicinal medicines, is suitable for treating various cancers such as liver cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, ovarian cancer, prostate cancer, esophagus cancer, pancreatic cancer, colon cancer, colorectal cancer, skin cancer, thyroid cancer, cervical carcinoma, leukemia and the like, can be used for preparing anti-cancer medicaments, realizes the application of the airpotato yam rhizome and Chinese angelica compositions to the preparation of medicaments for treating the cancers, develops the application range and the medicinal value of the airpotato yam rhizome and the Chinese angelica and makes creative contribution to the development of traditional Chinese medicine.

Disclosed herein are methods of inhibiting or delaying the growth of androgen-dependent prostate cancer, and / or inhibiting or delaying the onset of castration-resistant prostate cancer (CRPC) by administering naphthoquinone analogs, such as plumbagin, and specified hormone therapy agents, including selective inhibitors of 17,20-lyase activity of CYP 17.

The invention discloses a preparation method of lysimachia capillipes saponin A. The preparation method mainly comprises the following steps: selecting a lysimachia capillipes plant raw material, extracting the lysimachia capillipes plant raw material by adopting a water or ethanol-water mixed solvent, further purifying by adopting filler such as macroporous resin to obtain a total saponin extract rich in saponin B and C, dissolving the total saponin extract in an appropriate amount of alkaline solution, reacting at 40 to 80 DEG C, neutralizing by utilizing appropriate amount of acid, and further purifying the obtained hydrolysate by adopting filler such as macroporous resin, silica gel, reverse phase silica gel and the like, to obtain a lysimachia capillipes sapoonin A extract with content more than 90 percent. The invention also discloses an application of the lysimachia capillipes saponin A. The compound of the lysimachia capillipes saponin A has a remarkable inhibition effect on 11 human tumor cell lines such as A549 non-small cell lung cancer cells, SMMC-7721 human liver cancer cells, PC3 human prostate cancer cells and the like, has a broad-spectrum anti-cancer effect, and can be used as a drug or a medicine composition to treat malignant tumors.